Author

I. Sams

Observed name: Inga Sams

Institutions: The University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb (United States)

Observed institutions: The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, Bristol-Myers Squibb (United States), Quest Diagnostics (United States)

OpenAlex ID: A5003549477

High-dose (HD) imatinib in patients (pts) with previously untreated chronic myeloid leukemia (CML) in early chronic phase (CP): preliminary results of a multicenter community based trial

2005 · J. Cortes, F. Giles, et al. · Journal of Clinical Oncology · 11

Dasatinib (Sprycel™) Therapy for Patients with Systemic Mastocytosis.

2006 · Srdan Verstovsek, Hagop Kantarjian, et al. · Blood · 6

Dasatinib (BMS354825), a dual Src-Abl inhibitor, is active in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) following treatment failure with imatinib mesylate and AMN107

2006 · Z. Estrov, S. O’Brien, et al. · Journal of Clinical Oncology · 2

Dasatinib therapy for patients with Philadelphia-negative (ph-) myeloproliferative disorders (MPDs), including systemic mastocytosis

2007 · S. Verstovsek, E. Atallah, et al. · Journal of Clinical Oncology

Molecular monitoring of chronic phase chronic myeloid leukemia patients treated with 800 mg imatinib

2005 · M. Albitar, J. Cortes, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 19

H-index: 2

I10-index: 1